Related Experiment Videos
Imipenem versus moxalactam in the treatment of serious infections
Abstract:
Imipenem (formerly imipemide, N-formimidoyl thienamycin, or MK0787) was compared to moxalactam in a randomized therapeutic trial involving 39 evaluable patients with serious bacterial infections. Of those treated with imipenem, 89% were cured or improved versus 60% for moxalactam (P = 0.06). Although mucocutaneous fungal infections occurred in both groups (25 and 10%, respectively), Streptococcus faecalis superinfection was seen in two patients in the moxalactam group only. Adverse drug reactions occurred with both drugs, although bleeding occurred in three patients treated with moxalactam.
Insights
Imipenem demonstrated superior efficacy in treating serious bacterial infections compared to moxalactam, with higher cure rates and fewer adverse events. This study highlights imipenem as a potentially more effective antibiotic option.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Serious bacterial infections pose significant therapeutic challenges.
- Carbapenem antibiotics, like imipenem, offer broad-spectrum activity.
- Third-generation cephalosporins, such as moxalactam, are commonly used for severe infections.
Purpose of the Study:
- To compare the clinical efficacy and safety of imipenem versus moxalactam.
- To evaluate treatment outcomes in patients with serious bacterial infections.
Main Methods:
- A randomized therapeutic trial was conducted.
- 39 evaluable patients with serious bacterial infections were enrolled.
- Patients received either imipenem or moxalactam.
Main Results:
- Imipenem achieved an 89% cure or improvement rate, compared to 60% for moxalactam (P = 0.06).
- Mucocutaneous fungal infections were observed in 25% of imipenem patients and 10% of moxalactam patients.
- Streptococcus faecalis superinfection occurred in two moxalactam-treated patients; bleeding was noted in three moxalactam patients.
Conclusions:
- Imipenem showed a trend towards greater efficacy in treating serious bacterial infections.
- Moxalactam was associated with specific adverse events, including superinfection and bleeding.
- Further investigation into imipenem's role in managing severe bacterial infections is warranted.